Cargando…
Changes in Body Mass Index after Initiation of Antiretroviral Treatment: Differences by Class of Core Drug
Recent research on antiretroviral treatment (ART) for HIV suggests that integrase strand transfer inhibitors (INSTIs) cause faster weight gain compared to other drug classes. Here, we investigated changes in body mass index (BMI) and obesity prevalence after treatment initiation and corresponding di...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9415309/ https://www.ncbi.nlm.nih.gov/pubmed/36016299 http://dx.doi.org/10.3390/v14081677 |
_version_ | 1784776200359510016 |
---|---|
author | Pantazis, Nikos Papastamopoulos, Vasilios Antoniadou, Anastasia Adamis, Georgios Paparizos, Vasilios Metallidis, Simeon Sambatakou, Helen Psichogiou, Mina Chini, Maria Chrysos, Georgios Panagopoulos, Periklis Sipsas, Nikolaos V. Barbunakis, Emmanouil Gogos, Charalambos Touloumi, Giota |
author_facet | Pantazis, Nikos Papastamopoulos, Vasilios Antoniadou, Anastasia Adamis, Georgios Paparizos, Vasilios Metallidis, Simeon Sambatakou, Helen Psichogiou, Mina Chini, Maria Chrysos, Georgios Panagopoulos, Periklis Sipsas, Nikolaos V. Barbunakis, Emmanouil Gogos, Charalambos Touloumi, Giota |
author_sort | Pantazis, Nikos |
collection | PubMed |
description | Recent research on antiretroviral treatment (ART) for HIV suggests that integrase strand transfer inhibitors (INSTIs) cause faster weight gain compared to other drug classes. Here, we investigated changes in body mass index (BMI) and obesity prevalence after treatment initiation and corresponding differences between drug classes. Data were derived from a large collaborative cohort in Greece. Included individuals were adults who started ART, in or after 2010, while previously ART naïve and achieved virologic response within the first year of ART. Data were analysed using mixed fractional polynomial models. INSTI regimens led to the more pronounced BMI increases, followed by boosted PI and NNRTI based regimens. Individuals with normal initial BMI are expected to gain 6 kg with an INSTI regimen compared to 4 kg with a boosted PI and less than 3 kg with a NNRTI regimen after four years of treatment. Prevalence of obesity was 5.7% at ART initiation and 12.2%, 14.2% and 18.1% after four years of treatment with NNRTIs, PIs, and INSTIs, respectively. Dolutegravir or Raltegravir were associated with marginally faster BMI increase compared to Elvitegravir. INSTIs are associated with faster weight gain. INSTIs’ increased risk of treatment emergent obesity and, possibly, weight-related co-morbidities should be judged against their improved efficacy and tolerability but increased clinical attention is required. |
format | Online Article Text |
id | pubmed-9415309 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-94153092022-08-27 Changes in Body Mass Index after Initiation of Antiretroviral Treatment: Differences by Class of Core Drug Pantazis, Nikos Papastamopoulos, Vasilios Antoniadou, Anastasia Adamis, Georgios Paparizos, Vasilios Metallidis, Simeon Sambatakou, Helen Psichogiou, Mina Chini, Maria Chrysos, Georgios Panagopoulos, Periklis Sipsas, Nikolaos V. Barbunakis, Emmanouil Gogos, Charalambos Touloumi, Giota Viruses Article Recent research on antiretroviral treatment (ART) for HIV suggests that integrase strand transfer inhibitors (INSTIs) cause faster weight gain compared to other drug classes. Here, we investigated changes in body mass index (BMI) and obesity prevalence after treatment initiation and corresponding differences between drug classes. Data were derived from a large collaborative cohort in Greece. Included individuals were adults who started ART, in or after 2010, while previously ART naïve and achieved virologic response within the first year of ART. Data were analysed using mixed fractional polynomial models. INSTI regimens led to the more pronounced BMI increases, followed by boosted PI and NNRTI based regimens. Individuals with normal initial BMI are expected to gain 6 kg with an INSTI regimen compared to 4 kg with a boosted PI and less than 3 kg with a NNRTI regimen after four years of treatment. Prevalence of obesity was 5.7% at ART initiation and 12.2%, 14.2% and 18.1% after four years of treatment with NNRTIs, PIs, and INSTIs, respectively. Dolutegravir or Raltegravir were associated with marginally faster BMI increase compared to Elvitegravir. INSTIs are associated with faster weight gain. INSTIs’ increased risk of treatment emergent obesity and, possibly, weight-related co-morbidities should be judged against their improved efficacy and tolerability but increased clinical attention is required. MDPI 2022-07-29 /pmc/articles/PMC9415309/ /pubmed/36016299 http://dx.doi.org/10.3390/v14081677 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Pantazis, Nikos Papastamopoulos, Vasilios Antoniadou, Anastasia Adamis, Georgios Paparizos, Vasilios Metallidis, Simeon Sambatakou, Helen Psichogiou, Mina Chini, Maria Chrysos, Georgios Panagopoulos, Periklis Sipsas, Nikolaos V. Barbunakis, Emmanouil Gogos, Charalambos Touloumi, Giota Changes in Body Mass Index after Initiation of Antiretroviral Treatment: Differences by Class of Core Drug |
title | Changes in Body Mass Index after Initiation of Antiretroviral Treatment: Differences by Class of Core Drug |
title_full | Changes in Body Mass Index after Initiation of Antiretroviral Treatment: Differences by Class of Core Drug |
title_fullStr | Changes in Body Mass Index after Initiation of Antiretroviral Treatment: Differences by Class of Core Drug |
title_full_unstemmed | Changes in Body Mass Index after Initiation of Antiretroviral Treatment: Differences by Class of Core Drug |
title_short | Changes in Body Mass Index after Initiation of Antiretroviral Treatment: Differences by Class of Core Drug |
title_sort | changes in body mass index after initiation of antiretroviral treatment: differences by class of core drug |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9415309/ https://www.ncbi.nlm.nih.gov/pubmed/36016299 http://dx.doi.org/10.3390/v14081677 |
work_keys_str_mv | AT pantazisnikos changesinbodymassindexafterinitiationofantiretroviraltreatmentdifferencesbyclassofcoredrug AT papastamopoulosvasilios changesinbodymassindexafterinitiationofantiretroviraltreatmentdifferencesbyclassofcoredrug AT antoniadouanastasia changesinbodymassindexafterinitiationofantiretroviraltreatmentdifferencesbyclassofcoredrug AT adamisgeorgios changesinbodymassindexafterinitiationofantiretroviraltreatmentdifferencesbyclassofcoredrug AT paparizosvasilios changesinbodymassindexafterinitiationofantiretroviraltreatmentdifferencesbyclassofcoredrug AT metallidissimeon changesinbodymassindexafterinitiationofantiretroviraltreatmentdifferencesbyclassofcoredrug AT sambatakouhelen changesinbodymassindexafterinitiationofantiretroviraltreatmentdifferencesbyclassofcoredrug AT psichogioumina changesinbodymassindexafterinitiationofantiretroviraltreatmentdifferencesbyclassofcoredrug AT chinimaria changesinbodymassindexafterinitiationofantiretroviraltreatmentdifferencesbyclassofcoredrug AT chrysosgeorgios changesinbodymassindexafterinitiationofantiretroviraltreatmentdifferencesbyclassofcoredrug AT panagopoulosperiklis changesinbodymassindexafterinitiationofantiretroviraltreatmentdifferencesbyclassofcoredrug AT sipsasnikolaosv changesinbodymassindexafterinitiationofantiretroviraltreatmentdifferencesbyclassofcoredrug AT barbunakisemmanouil changesinbodymassindexafterinitiationofantiretroviraltreatmentdifferencesbyclassofcoredrug AT gogoscharalambos changesinbodymassindexafterinitiationofantiretroviraltreatmentdifferencesbyclassofcoredrug AT touloumigiota changesinbodymassindexafterinitiationofantiretroviraltreatmentdifferencesbyclassofcoredrug |